ArticleCureus2025
Attitudes and Knowledge Regarding Adipose-Derived Stem Cell Therapy: A Survey of Canadian Orthopedic Surgeons.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Adipose-derived stem cells (ADSCs) hold therapeutic potential for the treatment of orthopedic conditions. However, no surveys to date have evaluated physicians' awareness and receptiveness toward these therapies - an essential step in assessing the Canadian healthcare system's readiness for ADSC implementation, alongside regulatory and technical considerations. We hypothesized a generally low level of exposure to this therapeutic modality, with higher levels of awareness and interest expected among respondents specializing in sports medicine and reconstruction. Methods An eight-item questionnaire was distributed to members of the Arthroscopic Association of Canada and the Orthopedic Division at (redacted for blinding) University. Statistical analysis was conducted using mixed-effects logistic regression. Results The survey achieved a 12.9% response rate, yielding 50 responses. Most respondents (62%) reported hearing about ADSCs only a few times per year, primarily through scientific journals and colleagues. Only 10% expressed interest in incorporating ADSCs into their future practice. Common barriers included insufficient evidence, high costs, and regulatory limitations. No significant association was found between orthopedic subspecialty and receptiveness to ADSC therapy. Conclusions Canadian orthopedic surgeons show limited awareness of, and willingness to adopt, ADSC therapy in clinical practice. Contrary to our hypothesis, no significant differences were observed between subspecialties. Future studies should aim for larger, more representative samples to support more robust conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.